[HTML] frontiersin.org

[HTML][HTML] CAR T cell therapy for neuroblastoma

RM Richards, E Sotillo, RG Majzner - Frontiers in immunology, 2018 - frontiersin.org
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …
被引用次数：152 相关文章
[PDF] academia.edu

[PDF][PDF] CAR T Cell Therapy for Neuroblastoma

RM Richards, E Sotillo, RG Majzner - Front. Immunol. 9: 2380. doi …, 2018 - academia.edu
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …

CART Cell Therapy for Neuroblastoma

RM Richards, E Sotillo… - CAR-T Cell Therapies for …, 2020 - books.google.com
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …

CAR T Cell Therapy for Neuroblastoma

RM Richards, E Sotillo… - Frontiers in …, 2018 - pubmed.ncbi.nlm.nih.gov
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …

[引用][C] CAR T Cell Therapy for Neuroblastoma

RM Richards, E Sotillo, RG Majzner - Frontiers in Immunology, 2018 - cir.nii.ac.jp
CAR T Cell Therapy for Neuroblastoma | CiNii Research CiNii 国立情報学研究所 学術情報
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …
[HTML] frontiersin.org

[HTML][HTML] CAR T Cell Therapy for Neuroblastoma

RM Richards, E Sotillo, RG Majzner - Frontiers in Immunology, 2018 - frontiersin.org
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …

CAR T Cell Therapy for Neuroblastoma.

RM Richards, E Sotillo, RG Majzner - Frontiers in Immunology, 2018 - europepmc.org
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …
[HTML] nih.gov

[HTML][HTML] CAR T Cell Therapy for Neuroblastoma

RM Richards, E Sotillo, RG Majzner - Frontiers in Immunology, 2018 - ncbi.nlm.nih.gov
Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with
debilitating long term sequelae from treatment. Even after integration of anti-GD2 …